In this interview, David Flores sits down with Cody Shandraw, the managing partner at Ambria Capital.
Ambria Capital is an investment firm which focuses on investing in psychedelic therapies and technologies. In this episode they discuss the psychedelic space in general and Ambria’s approach to investing.
Cody acknowledges that many companies in the space will fail, but the ones who succeed will transform the mental health landscape. That is a risk that Ambria Capital is willing to take to be involved in the psychedelic transformation that is unfolding.
Psychedelics are changing people's lives, and Ambria Capital wants to make sure that these companies are financed to do so…And maybe make some money on the successful companies.
Cody acknowledges that his family has had lots of addiction issues, so this issue is personal for him. If psychedelics can help addiction, it would be a game changer.
Cody discusses how the most important thing for deciding which company to invest in, is the management teams, regardless of whether they work with psilocybin, lsd, mescaline or other compounds.
Cody really likes PsyHealth.
We all know someone who has been affected by addiction, depression, anxiety, or other mental health issues. We all want to find solutions to help these people.
#AmbriaCapital #Psychedelics #PsychedelicTherapy
Have you heard about our new community?
We’re excited to announce Bonfire -
a personal growth community for people who are interested in psychedelics.
Join us for our launch event on July 18th, where we’ll share about the work we’ll be doing together to actualize our personal missions, grow, and heal together.
Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.